ÃâÒßÇòµ°°×A£¨IgA£©½á¹¹¡¢·ÖÀ༰¹¦ÄܽéÉÜ

ÃâÒßÇòµ°°×A£¨IgA£©ÊǺôÎüµÀ¡¢Î¸³¦µÀµÈð¤Ä¤±íÃæ·ÖÃÚÎïÖеÄÖ÷Òª¿¹ÌåÀà±ð£¬ÓÉIgMͨ¹ý¿¹ÌåÀà±ðת»»¶øÀ´¡£IgA¾ßÓÐÒÖÖÆϸ¾úºÍ²¡¶¾ÓëÉÏƤϸ°ûµÄÕ³¸½£¬ÖкÍϸ°ûÄÚÍⲡ¶¾ºÍϸ¾ú¶¾ËصŦÄÜ£¬±»ÈÏΪÊǵÖÓùÐí¶àÈëÇÖ²¡Ô­ÌåµÄÖØÒªµÚÒ»µÀ·ÀÏß¡£IgAÒ²ÊÇÒ»ÖÖ½ÏÈõµÄ²¹Ì弤»î¼Á£¬ÔÚ¿¹Ô­ÓÐÏÞµÄÇé¿öÏ£¬Í¨¹ý×è¶ÏÇ¿¼¤»î²¹Ìå¼ÁIgG»òIgM¿¹ÌåµÄ½áºÏÒÖÖƲ¹Ì弤»î¡£

IgAµ¥Ìå½á¹¹¼°·ÖÀà

ÓëÆäËüÃâÒßÇòµ°°×£¨Ig£©Ïàͬ£¬IgAµ¥ÌåÒ²ÓÉ2ÌõÏàͬµÄÖØÁ´ºÍÇáÁ´×é³É£¬¶¥¶Ë2¸öFabÇø¿Éʶ±ð¿¹Ô­£¬FcÇø¿ÉÓë¸÷ÖÖÊÜÌåºÍЧӦ·Ö×ÓÏ໥×÷Óá£FabÇøºÍFcÇøÓÉÒ»¸öÁé»îµÄ½ÂÁ´Çø¸ô¿ª¡£ÓëÆäËûIg²»Í¬£¬IgAÖØÁ´Îª¦ÁÁ´£¬CH3°üº¬Ò»¸ö³ÆΪβ²¿£¨Tp£©µÄ18¸ö°±»ùËáCÄ©¶ËÑÓÉì¡£

ÔÚÈËÌåÄÚIgA´æÔÚIgA1ºÍIgA2Á½¸öÑÇÀ࣬IgA1ÊÇÈ«ÉíÃâÒßϵͳ²úÉúµÄÖ÷ÒªIgAÑÇÀ࣬IgA2Ö÷Òª´æÔÚÓڽ᳦¡£IgA1¡¢IgA2ÖØÁ´ºã¶¨Çø£¨¼´C¦Á1¡¢½ÂÁ´¡¢C¦Á2ºÍC¦Á3£©½ÂÁ´ÐòÁвîÒìÏÔÖø£¨Í¼1£©¡£IgA1°üº¬Ò»¸öÖظ´µÄ°ËëÄÐòÁУ¬·¶Î§´óÒ×Ë®½â£»IgA2Ãô¸Ð½ÂÁ´ÇøÐòÁÐȱʧ£¬¿¹µ°°×øˮ½âÄÜÁ¦¸üÇ¿¡£IgA2°üº¬IgA2m£¨1£©ºÍIgA2m£¨2£©Á½ÖÖͬÖÖÒìÐÍ£¬IgA2m£¨2£©µÄH¡¢LÁ´Í¨¹ý¶þÁò¼üÁ¬½Ó£¬½á¹¹Îȶ¨£»IgA2m£¨1£©Í¨¹ý·Ç¹²¼ÛÏ໥×÷Ó㬽ṹËÉÉ¢Ò×·ÖÀë¡£·Ö×ӽṹÏÔʾIgA1µÄ2¸öFab¶¥¶Ë¼ä¾à±ÈIgA2m£¨1£©¸ü´ó£¨Í¼2£©£¬Îª´ËIgA1¿ÉÄܶԱíÃæ¾ßÓÐÖظ´¿¹Ô­½á¹¹µÄ²¡Ô­ÌåÓиü¸ßµÄÇ׺ÍÁ¦¡£

ͼ1 ÈËIgA1ºÍIgA2½ÂÁ´Çø±È½Ï

ͼ2 ÈËIgA1ºÍIgA2m£¨1£©·Ö×ÓÄ£ÐÍ

×¢£ºIgA1¡¢IgA2m£¨1£©ÇáÁ´ÎªÂÌÉ«£»IgA1ÖØÁ´Îª×ÏÉ«£¬IgA2m£¨1£©ÖØÁ´ÎªÇàÉ«¡££¨Í¼Æ¬À´Ô´Óڲο¼ÎÄÏ×^[3]£©

ÌìÈ»IgAµÄ´æÔÚÐÎʽ

IgAÔÚÌåÄÚÓзÖÃÚÐÍIgA£¨SIgA£©ºÍѪÇåIgAÁ½ÖÖ£¬·Ö±ðÀ´Ô´ÓÚ·Ö²¼ÓÚð¤Ä¤Ïà¹ØÁÜ°Í×éÖ¯µÄ½¬Ï¸°ûºÍ¹ÇËè¼°ÍâǨÖÁÆ¢ÖеĽ¬Ï¸°û¡£·ÖÃÚÐÍIgA£¨SIgA£©´æÔÚÓÚÍÙÒº¡¢ÑÛÀá¡¢³õÈé¡¢³¦µÀ¡¢ÉúÖ³µÀÒÔ¼°ºôÎüµÀµÄ·ÖÃÚÎïÖУ¬´ó¶àÒÔ¾ÛºÏÎpIgA£©ÐÎʽ´æÔÚ£¬Ö÷ÒªÓɶþ¾ÛÌ壨dIgA£©×é³É¡£·ÖÃÚÐÍIgA£¨SIgA£©·Ö×ÓÁ¿Îª385 kD£¬Æ½¾ùѪÇåŨ¶ÈΪ0.05 mg/mL¡£pIgAÓÉIgAµ¥ÌåFcÇøÓëJÁ´Î²²¿µ¹ÊýµÚ¶þ¸öCys²Ð»ùͨ¹ý¶þÁò¼üÁ¬½Ó¶ø³É¡£Óëµ¥ÌåÏà±È£¬pIgAº¬Óжà¸öFab£¬¾ßÓиüÇ¿µÄ¿¹Ô­Ç׺ÍÁ¦£¬¸üÒ×ÓÚÄý¼¯Íⲿ·ÖÃÚÎïÖеÄ΢ÉúÎï¡£

ѪÇåIgAÖ±½Ó·ÖÃÚµ½ÑªÒºÖУ¬ÒÔµ¥ÌåÐÎʽ´æÔÚ£¬ÆäÖÐÔ¼90%ÊÇÔÚ¹ÇËèÖвúÉúµÄIgA1µ¥Ì塣ѪÇåIgA·Ö×ÓÁ¿Îª160 kD×óÓÒ£¬Õ¼×ÜIgµÄ10%¨C15%£¬Å¨¶È½ö´ÎÓÚIgG£¨12 mg/mL£©Ô¼Îª2-3 mg/mL£¬²úÉúËÙÂÊÓëIgGÏàËÆ£¬µ«´úлËٶȱÈIgG¿ìÎ屶¡£

ͼ3 ÈËIgA1¡¢IgA2m£¨1£©¡¢IgA2m£¨2£©¡¢dIgA1ÒÔ¼°SIgA1ʾÒâͼ

×¢£ºÖØÁ´ºã¶¨ÇøΪºìÉ«£¬¿É±äÇøΪ·ÛºìÉ«¡£ÇáÁ´ºã¶¨ÇøΪÀ¶É«£¬¿É±äÇøΪµ­À¶É«¡£JÁ´Îª»ÆÉ«£¬·ÖÃڳɷÖΪ×ÏÉ«¡£ÔÚIgAµÄµ¥ÌåÐÎʽÉÏ£¬O-ÌÇ»ù»¯ÎªÂÌÉ«£¨ÔÚIgA1½ÂÁ´ÉÏ£©£¬N-ÌÇ»ù»¯ÎªÉîÀ¶É«¡££¨Í¼Æ¬À´Ô´Óڲο¼ÎÄÏ×^[3]£©

IgAתÔË»úÖƼ°¹¦ÄÜ

pIgR½éµ¼µÄIgAð¤Ä¤ÉÏƤתÔ˼°¹¦ÄÜ

IgAÓÉð¤Ä¤ÉÏƤ¹ÌÓвãÖеľֲ¿½¬Ï¸°û£¨PC£©²úÉú¡£pIgAͨ¹ýJÁ´Óë¾ÛºÏÃâÒßÇòµ°°×ÊÜÌ壨pIgR£©ÔÚ»ùµ×Íâ²à±íÃæ½áºÏ£¬ÐγɵÄpIgR-IgA¸´ºÏÎï±»ÄÚÍÌ£¨Í¼4-¢Û£©²¢Í¨¹ýһϵÁÐÄÒÅÝ´©¹ýϸ°û±»´«µÝµ½¶¥¶Ë±íÃæ¡£ÔÚ¶¥¶Ë±íÃæµÄpIgRµ°°×Ë®½â£¬ÊÍ·ÅSC-pIgA¸´ºÏÎSIgA£©»òÓÎÀë·ÖÃڳɷ֣¨SC£©£¨Í¼4-¢Ü£©¡£SCÊÇÒ»ÖÖÇ×Ë®ÐԺ͸߶ÈÌÇ»ù»¯´ø¸ºµçºÉµÄ·Ö×Ó£¬ÔÚÇ»·ÖÃÚÎïÖУ¬IgAÓëSCµÄ¹²¼ÛżÁª¿ÉÒÔÌáÉýSIgAµÄÇ×Õ³ÌØÐԺͿ¹µ°°×øˮ½âµÄÎȶ¨ÐÔ¡£

תÔ˹ý³ÌÖÐpIgA¿ÉÒÔ½áºÏ¡¢ÖкͺÍÏû³ý²¡¶¾¡£½þÈóµÄ¿¹Ô­ºÍ²¡Ô­Ìå±»pIgAתÔ˻عÜÇ»¡£ÑÇÉÏƤÊ÷ͻ״ϸ°û£¨DC£©¿ÉÒԳʵݿ¹Ô­»òÎüÊÕͨ¹ý΢ÖåñÞϸ°û£¨Mϸ°û£©½øÈëµÄSIgA°ü±»µÄ²¡Ô­Ìå¡£¹ÌÓвãÖеIJ¡Ô­Ìå±»dIgA°ü±»ÐγÉÃâÒ߸´ºÏÎÓɱí´ïFc¦ÁRIµÄDCºÍÖÐÐÔÁ£Ï¸°ûÉãÈ¡¡£ÖÐÐÔÁ£Ï¸°û·ÖÃÚ°×ÈýÏ©B4£¨LTB4£©£¬ÎüÒý¸ü¶àµÄÖÐÐÔÁ£Ï¸°û£¬´Ó¶øÇå³ý¸ÐȾ¡£

ͼ4 ¾ÛºÏÃâÒßÇòµ°°×ÊÜÌ壨pIgR£©½éµ¼µÄIgAð¤Ä¤ÉÏƤתÔËʾÒâͼ

×¢£ºÍ¼ÖÐΪÉÏƤµÄ¼ò»¯ºá½ØÃ棬¶¥²¿ºÍµ×²¿·Ö±ð¾ßÓж¥¶ËºÍ»ùµ×Íâ²à±íÃæ¡£pIgRΪ³ÈÉ«£¬¾ÛºÏIgAΪºìÉ«£¬Ï¸°ûºË£¨N£©ºÍÄÚÖÊÍøΪ»ÒÉ«£¬Ï¸¾ú²¡Ô­ÌåΪÉîÀ¶É«ºÍ·ÛºìÉ«£¬²¡¶¾²¡Ô­ÌåΪºÚÉ«ÁâÐΡ£BEEΪ»ùµ×Íâ²àÔçÆÚºËÄÚÌ壻CEΪ¹²ºËÄÚÌ壻AREΪ¶¥¶ËÔÙÑ­»·ÄÚÌ壻AEEΪ¶¥¶ËÔçÆÚÄÚÌå¡££¨Í¼Æ¬À´Ô´Óڲο¼ÎÄÏ×^[3]£©

³¦µÀϵͳÖеÄSIgA¹¦ÄÜ

SIgAÔÚά³Ö¶ÔÎÞº¦¹²ÉúÎïµÄÄÍÊܼ°²¡Ô­ÌåÃâÒßÁ¦Æ½ºâ·½Ãæ¾ßÓÐÖØÒª×÷Óá£ÔÚ³¦µÀϵͳÖУ¬SIgA´ÓÉÏƤ²ãÊͷŵ½¹ÜÇ»£¬´æÔÚÓÚÍâÕ³Òº²ãÖУ¬SIgAÍ¿²ã·¢»Ó·Ö×Ó¡°ÓÍÆᡱ×÷Ó㬸ÉÈÅϸ¾úÔ˶¯²¢°üΧ¾ßÓÐÇ×Ë®Íâ¿ÇµÄ²¡Ô­Ì壬×èÖ¹²¡Ô­Ìå½øÈ볦ÉÏƤ¡£SIgAͨ¹ý¿¹Ìå½éµ¼µÄ±íÃ濹ԭ½»Áª»áÄý¼¯Ï¸¾ú£¬ÖкÍø¡¢¶¾ËصÈϸ¾ú²úÎÔÙͨ¹ý³¦È䶯ȥ³ýϸ¾ú¾Û¼¯Ìå¡£SIgAÓëÕ³Òº²ãÐγɵֿ¹²¡Ô­Î¢ÉúÎïµÄÌìÈ»ÆÁÕÏ£¬¹²Í¬·ÀÖ¹²¡Ô­Î¢ÉúÎïÔÚð¤Ä¤ÉÏƤ¶¨Ö²ºÍÉø͸£¬±ÜÃâ¸ÐȾ¡£

Fc¦ÁRI½éµ¼µÄIgA¹¦ÄÜ

ѪÇåIgAÃâÒ߸´ºÏÎïͨ¹ýÇ׺ÍÁ¦½áºÏ²¢½»ÁªFc¦ÁRI¼¤»îÃâÒßϸ°û£¬´Ó¶øÓÕµ¼´ÙÑ×·´Ó¦£¬Ïû³ý²¡Ô­Ìå¡£µ¥ÌåIgAͨ¹ý¿ÉÄÜIgAFcÊÜÌ壨Fc¦ÁRI£»CD89£©ÒÖÖÆITAMiÐźŴ«µ¼Î¬³ÖÎÈ̬¡£ÓÉÓÚpIgRÏ໥×÷ÓÃλµãÓëFc¦ÁRI²¿·ÖÖصþ£¬SIgAÓëFc¦ÁRI½áºÏÊÜ×裬ÎÞ·¨Í¨¹ýFc¦ÁRI´Ù½øÍÌÊÉ×÷Ó㬵«SIgAÄܹ»Í¨¹ýFc¦ÁRIºÍÄý¼¯ËØMac-1£¨CD11b/CD18£©µÄ¹²Í¬´Ì¼¤ºôÎü±¬·¢¡£ÓëIgG»òIgMÏà±È£¬IgAÔÚ´ÓѪҺÖÐÇå³ý²¡¶¾µÄ×÷ÓúÜС£¬²¢ÇÒ¶ÔÓÚÔٴνӴ¥²¡¶¾ºó¶ÔÈ«ÉíÐÔ²¡¶¾µÄ±£»¤ÐÔÃâÒßÊǷDZØÐèµÄ¡£

²Î¿¼ÎÄÏ×
[1] Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2[J]. Sci Transl Med, 2021, 13(577):eabd2223.
[2] Wang Z, Lorenzi JCC, Muecksch F,et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA[J]. Sci Transl Med, 2021, 13(577):eabf1555.
[3] Macpherson, A., McCoy, K., Johansen, FE., et al. The immune geography of IgA induction and function[J]. Mucosal Immunol, 2008, 1(1):11¨C22.
[4] Breedveld A, van Egmond M. IgA and Fc¦ÁRI: Pathological Roles and Therapeutic Opportunities[J]. Front Immunol, 2019, 10: 553.

Ïà¹Ø·þÎñ

Ïà¹ØÔĶÁ

• IgAÓëIgGµÄ½á¹¹¡¢¹¦ÄܲîÒì